Incentive Compensation
A multifold approach towards the “new normal” to ensure fair and motivating compensation plans.
With COVID-19-imposed nationwide lockdowns, weak field productivity, and detailing restrictions, the pandemic is directly impacting the Incentive Compensation (IC) of reps across the pharma industry. Companies also continue to struggle to alleviate the sales teams’ health and monetary fears. A right incentive strategy can motivate sales reps and provide a sense of financial security.
A robust IC program to withstand the business fluctuations imposed by the pandemic.
The continuous motivation for sales reps with balanced pay outs and exciting rewards.
Insulation from market variations and different geographic behavior through the COVID-19 impacted period.
Read this illustration to know about Axtria’s multi-fold approach towards creating a COVID-19 immune incentive compensation plan for a pharma company.
Download the free case study here.
Contact us at insights@axtria.com with any questions.
Complete the brief form to download the white paper
Recommended insights
Press Release
Axtria Unveils New US and Global Incentive Compensation Benchmarking Studies: Insights That Drive Life Sciences Success
Report
2024 US Incentive Compensation Benchmarking Study
Report